SkyOak Wealth’s VYNE Therapeutics VYNE Stock Holding History

SkyOak Wealth’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,511	Closed	-$28K	–	272
2021 Q4	$28K	Buy	+1,511	New	+$32.4K	0.01%	245

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

SkyOak Wealth's VYNE Position: Q1 2022 in Review

SkyOak Wealth sold out of VYNE Therapeutics (VYNE) in Q1 2022, closing a stake of 1,511 shares — an estimated $28K sold.

SkyOak Wealth first reported a position in VYNE in Q4 2021 and held it in 1 quarter. The position peaked at $28K in Q4 2021. 44 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

SkyOak Wealth reported no remaining VYNE Therapeutics position as of Q1 2022 after selling out during the quarter.
SkyOak Wealth sold 1,511 VYNE Therapeutics shares in Q1 2022, an estimated $28K.
SkyOak Wealth first reported a position in VYNE Therapeutics in Q4 2021 and held it in 1 quarter.
SkyOak Wealth's VYNE Therapeutics position peaked at $28K in Q4 2021.
44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on SkyOak Wealth's 13F filing for Q1 2022, filed 18 Apr 2022.